La glycoprotéine M (gM) est une protéine virale transmembranaire qui est conservée dans la famille des Herpesviridae. Malgré son rôle non essentiel in vitro chez la plupart des virus de la sous-famille des Alphaherpesvirinae, dont l’herpès simplex de type 1 (VHS-1), gM est impliquée à plusieurs étapes de leur cycle viral et sa déplétion entraine une diminution de la production virale. Pour effectuer ses diverses fonctions, gM est ciblée dynamiquement à plusieurs compartiments cellulaires au cours de l’infection, dont le noyau, le réseau trans-Golgi et la membrane plasmique. Chez le VHS-1, gM est la première glycoprotéine détectée aux membranes nucléaires, et ce, dès 4 heures après le début de l’infection. Des expériences effectuées précédemment dans notre laboratoire ont démontré que la localisation de gM au noyau à 4hpi est un processus actif, viral-dépendant et spécifique qui succède sa traduction au réticulum endoplasmique. Or, sa fonction au noyau n’est toujours pas élucidée, ni le mécanisme lui permettant d’atteindre ce compartiment tôt durant l’infection. D’ailleurs, aucun des partenaires d’interaction connus de gM n’a été identifié comme participant à ce ciblage, soulevant des questions quant au mécanisme utilisé par la glycoprotéine virale pour atteindre le noyau. Notre hypothèse est que gM emprunte le transport nucléocytoplasmique de la cellule pour être activement ciblée à la membrane nucléaire interne par l’intermédiaire des importines. Afin d’étudier le rôle des importines dans la localisation de gM tôt dans l’infection, chaque importine a été déplétée par ARN interférent dans des cellules 143B. À la suite d’une infection de 4h, la localisation de gM a été déterminée par microscopie confocale suivie d’analyses qualitatives en 2D et en 3D. Les résultats obtenus suggèrent que les importines ne participent pas significativement au ciblage de gM aux membranes nucléaires à cette étape de l’infection. Ces observations ouvrent la porte à d’autres mécanismes de transport qui devront être étudiés afin de mieux comprendre le ciblage de gM à ce compartiment et, éventuellement, y déterminer son ou ses rôles dans le cycle viral de l’herpès. / Glycoprotein M (gM) is a viral transmembrane protein that is conserved in the Herpesviridae family. Despite its non-essential role in vitro in most viruses of the Alphaherpesvirinae subfamily, including herpes simplex virus type 1 (HSV-1), gM is involved at several stages of their viral cycle and its depletion leads to a decrease in viral production. To perform its various functions, gM is dynamically targeted to several cellular compartments during infection, including the nucleus, the trans-Golgi Network and the plasma membrane. In HSV-1, gM is the first glycoprotein detected at nuclear membranes as early as 4 hours after the onset of infection. Previous experiments conducted in our laboratory have shown that the localization of gM to the nucleus at 4hpi is an active, viral-dependent and specific process that follows its translation at the endoplasmic reticulum. However, its function at the nucleus is still not elucidated, nor is the mechanism by which it reaches this compartment early during infection. Moreover, none of gM's known interacting partners have been identified as participants in this targeting, raising questions about the mechanism used by the viral glycoprotein. Our hypothesis is that gM takes advantage of the nucleocytoplasmic transport of the cell to be actively targeted to the inner nuclear membrane via importins. In order to study the role of the importins in the localization of gM early in the infection, each importin was depleted by interfering RNA in 143B cells. After a 4-hour infection, gM localization was determined by confocal microscopy followed by 2D and 3D qualitative analysis. The results obtained from these experiments suggest that importins do not significantly participate in the targeting of gM to nuclear membranes at 4hpi. These observations open the door to other transport mechanisms that will need to be studied in order to better understand the targeting of gM to this compartment and to eventually determine its role(s) in the herpes viral cycle.

Impairment of mucociliary clearance with reduced airway fluid secretion leads to chronically inflamed airways. Cystic fibrosis transmembrane conductance regulator (CFTR) is crucially involved in airway fluid secretion and dexamethasone (dexa) has previously been shown to elevate CFTR activity in airway epithelial cells. However, the pathway by which dexa increases CFTR activity is largely unknown. We aimed to determine whether the increase of CFTR activity by dexa is achieved by non-genomic signaling and hypothesized that the phosphoinositide 3-kinase (PI3K) pathway is involved in CFTR stimulation. Primary rat airway epithelial cells and human bronchial submucosal gland-derived Calu-3 cells were analyzed in Ussing chambers and kinase activation was determined byWestern blots. Results demonstrated a critical involvement of PI3K and protein kinase B (AKT) signaling in the dexa-induced increase of CFTR activity, while serum and glucocorticoid dependent kinase 1 (SGK1) activity was not essential. We further demonstrated a reduced neural precursor cell expressed, developmentally downregulated 4-like (NEDD4L) ubiquitin E3 ligase activity induced by dexa, possibly responsible for the elevated CFTR activity. Finally, increases of CFTR activity by dexa were demonstrated within 30 min accompanied by rapid activation of AKT. In conclusion, dexa induces a rapid stimulation of CFTR activity which depends on PI3K/AKT signaling in airway epithelial cells. Glucocorticoids might thus represent, in addition to their immunomodulatory actions, a therapeutic strategy to rapidly increase airway fluid secretion.

Fibronectin is an extracellular multidomain glycoprotein that directs and regulates a variety of cell processes such as proliferation, development, haemostasis, embryogenesis, and wound healing. As a major component of blood, fibronectin exists as a soluble disulphide linked dimer, but it can also be incorporated into an insoluble cross-linked fibrillar network to form a major component of the extracellular matrix. Fibronectin is composed of an extended chain of module repeats termed Fn1, Fn2, and Fn3 that bind to a wide range of transmembrane receptors and extracellular matrix components, including collagen. The gelatin binding domain of fibronectin was first isolated as a 45kDa proteolytic fragment and has since been found to be composed of six modules: 6Fn1-1Fn2-2Fn2-7Fn1-8Fn1-9Fn1 (in this notation nFX represents the nth type X module in the native protein). This domain has been reported to bind to both collagen and denatured collagen (gelatin), but with 10-100 times higher affinity to the latter; it can be purified to homogeneity on a gelatin affinity column. In the work presented here, fragments of the gelatin binding domain are expressed in P. pastoris, purified to homogeneity, and investigated at the molecular level. Through a dissection approach, surface plasmon resonance (SPR) is used to characterise the recombinantly produced protein, to accumulate more information about the function of the full domain. NMR is used to assess the folding of the protein fragments at atomic resolution. In particular, the secondary structure of 8Fn1-9Fn1 is mapped using inter-strand NOEs, which suggests that the construct takes the fold of a pair of typical Fn1 modules. Gelatin affinity chromatography is used to confirm that both Fn1 and Fn2 modules contribute to gelatin binding, possibly in two clusters (1Fn2-2Fn2 and 8Fn1-9Fn1). The 7Fn1 module may perform a structural role in linking together these two interaction sites, in the same way as suggested for 6Fn1, which is thought to act in a structural manner to enhance the binding of 1Fn2-2Fn2 to gelatin. Three carbohydrate moieties are found on this domain, one on 2Fn2 and two on 8Fn1. Here, by means of expressing different protein length fragments, and by site directed mutagenesis, the role of each sugar chain is investigated independently. The sugar chain on 2Fn2 does not appear to promote binding to collagen, nor does the first sugar chain on 8Fn1 (N-linked to N497), implying another role for these sugars such as protection from proteolysis. However, the presence of at least a single GlcNAc sugar residue on the second sugar chain site on 8Fn1 (N- linked to N511) is essential for full affinity binding to collagen. Direct binding of the 8Fn1-9Fn1 module pair to collagen is assessed with a short collagen peptide and the binding is monitored by NMR. The peptide appears to bind, predominantly to the final strand of 8Fn1, the first β- strand of 9Fn1, and the linker between the two modules, with μM affinity. A model for bound peptide is proposed. The highly conserved amino acid motif Ile-Gly-Asp (IGD) is found on four of the nine N-terminal Fn1 modules of fibronectin. Tetrapeptides containing the IGD were demonstrated to promote the migration of fibroblast cells into a native collagen matrix. Two of these “bioactive” IGD motifs are found within the gelatin binding domain, one on 7Fn1 and one on 9Fn1. In this study, the motif in the 8Fn1-9Fn1 module pair is shown to be located in a tightly constrained loop within 9Fn1. By site directed mutagenesis, the IGD motifs of 7Fn1 and 9Fn1 are subjected to single amino acid substitutions, and their ability to stimulate cell migration assessed in our assay. By NMR, the fold of the IGD mutant proteins is found to be unaffected by the mutation with respect to the wild type, with the exception of small perturbations around the substitution site. While the wild type module is able to stimulate fibroblast migration, the mutant proteins show reduced or negligible bioactivity. The larger fragments show far more potency in stimulating fibroblast migration, with 8Fn1-9Fn1 (one IGD motif) 104 times more potent than the IGD peptide, and the full gelatin binding domain (two IGD motifs) 106 times more potent than the 8Fn1-9Fn1. Potential mechanisms for this enormous enhancement of the IGD potency in different contexts are discussed.

<p>Uvod: Nespecifičnost kliničke slike sepse, velike individualne razlike u odgovoru organizma na infekciju kao i neophodnost adekvatne inicijalne procene težine kliničke slike, toka i ishoda bolesti, čine istraživanja biomarkera koji bi doprineli pravovremenom postavljanju dijagnoze i adekvatnoj prognozi bolesti izuzetno značajnim. Do sada je ispitivano preko 200 biomarkera od kojih ni jedan nije pokazao zadovoljavajuću senzitivnost i specifičnost. Uloga B limfocita u patogenezi sepse pri tome je nedovoljno istražena. Članovi superfamilije tumor-nekrozis faktora alfa: A proliferation inducing ligand (APRIL), Bcell activating factor (BAFF) i solubilni transmembrane activator and calcium modulator cyclophilin ligand interactor (sTACI) su citokini koji imaju ključnu ulogu u homeostazi B limfocita. Cilj istraživanja bio je da se ispita dijagnostički i prognostički značaj citokina članova superfamilije tumor nekrozis faktora alfa (APRIL, BAFF, sTACI) za procenu težine kliničke slike, razvoja multiorganske disfunkcije (MODS) u prvih 48h hospitalizacije i letalnog ishoda sepse. Ispitanici i metode: Istraživanjem je obuhvaćeno 150 obolelih od sepse lečenih na Klinici za infektivne bolesti i Odeljenju anestezije i reanimacije Kliničkog centra Vojvodine i 30 zdravih dobrovljnih davalaca krvi. Kod svih bolesnika evidentirani su demografski i ostali podaci iz istorije bolesti kao i laboratorijske analize u okviru rutinske dijagnostike sepse. Iz dodatnih 5ml venske krvi svim ispitanicima određene su koncentracije APRIL-a, BAFF-a, sTACI-ja ELISA metodom komercijalnim testovima proizvođača R&amp;D Systems. Rezultati pokazuju da su koncentracije sva tri citokina (APRIL, BAFF i sTACI) statistički značajno povi&scaron;ene kod obolelih od sepse u odnosu na zdravu populaciju (p&lt;0.001), pri čemu APRIL pokazuje najveću senzitinvost (99%) i specifičnost (97%). Najveći dijagnostički značaj BAFF-a ogleda se u sposobnosti distinkcije između sepsi uzrokovanih Gram pozitivnim i Gram negativnim bakterijama (p=0,03). U predikciji razvoja MODS-a i letalnog ishoda sepse multivarijantnom regresionom analizom kao nezavisni prediktori pokazali su se jedino antiinflamatorni biomarker sTACI receptor i klinička procena pacijenta iskazana kroz APACHE II i SOFA skor. Senzitivnost i specifilnost sTACI receptora u predikciji razvoja MODS-a i letalnog ishoda daleko nadma&scaron;uje do sada rutinski kori&scaron;ćen prokalcitonin. Zaključak: Dobijeni rezultati ukazuju na to da su citokini koji učestvuju u regulaciji funkcije B limfocita značajni dijagnostički i prognostički parametri u sepsi. Predominacija antiinflamatornog odgovora na koju ukazuju povi&scaron;ene koncentracije sTACI receptora pokazala se pored APACHE II i SOFA skora kao jedini nezavisni prediktor razvoja MODS-a i letalnog ishoda septičnih bolesnika. Neophodna su dalja istraživanja u pravcu određivanja momenta kada u imunskom odgovoru organizam prelazi iz stanja dominacije proniflamatornog u dominaciju antiinflamatornog odgovora radi pravovremenog reagovanja imunomodulatornom terapijom.</p> / <p>Introduction: The nonspecific clinical presentation of sepsis and great individual response variations, as well as huge significance of adequate early prognosis of its clinical course and outcome made sepsis biomarkers research extremely significant. The properties of more than 200 biomarkers have been evaluated for prognostic value, but none have adequate specificity and sensitivity. The role of the B cells in sepsis pathogenesis also remains unclear. Tumor necrosis factor alpha (TNF-&alpha;) superfamily members: A proliferation inducing ligand (APRIL), Bcell activating factor (BAFF) and soluble transmembrane activator and calcium modulator cyclophilin ligand interactor (sTACI) are key factors in B cell biology. The aim of the study was to evaluate the diagnostic and prognostic significance of determining the concentrations of tumor necrosis factor alpha superfamily members for the prediction of MODS development in the first 48h of hospitalization as well as outcome prediction.<br />Subjects and methods: The study included 150 patients suffering from sepsis treated at the Clinic for infectious diseases and Department for anesthesiology and reanimatology of the Clinical center of Vojvodina, and 30 healthy volunteer blood donors. The demographic and other data regarding routine blood analysis performed during sepsis treatment of the patients has been acquired from their hospitalization documentation. Additional 5 ml of venous blood was taken from the patients and the concentrations of APRIL, BAFF and sTACI have been determined using the ELISA method by using R&amp;D Systems commercial kit&rsquo;s. Results: There is a statistically significant difference in concentrations of APRIL, BAFF and sTACI between healthy blood donors and septic patients (p&lt;0.001). APRIL showed the highest sensitivity (99%) and specificity (97%) in distinguishing sepsis from healthy subjects. BAFF showed statistically significant higher concentrations in Gram positive than in Gram negative sepsis (p=0,03). In the multivariate logistic regression analysis, only anti-inflammatory cytokine sTACI and APACHE II or SOFA score remained significant predictors of MODS and lethal outcome. sTACI showed greater sensitivity and specificity for MODS and outcome prediction then the widely used procalcitonin.&nbsp; Conclusions: The concentrations of TNF superfamily members, the main regulators of B cell function, have a significant diagnostic and prognostic value in predicting sepsis course and outcome. The predomination of the anti-inflammatory response, as being pointed out by elevated concentrations of sTACI receptors, has proved to be the only independent predictor, besides APACHE II and SOFA score, in MODS and lethal outcome development in sepsis. Further research is needed in order to accurately determine the exact moment when the immunological response shifts from the predominance of the pro-inflammatory response to the predominance of the anti-inflammatory response, so as to ensure the timely application of therapy that modulates the immunological response.</p>

Die für die Vermehrung der Paramyxoviren notwendige Freisetzung des Virusgenoms in die Wirtszelle findet nach einer Verschmelzung der Virushülle mit der Zellmembran statt. Die Membranfusion wird durch eine Konformationsänderung des membranständigen Fusionsproteins (F-Protein) der Paramyxoviren vermittelt. Der Auslöser der Strukturumwandlung des F-Proteins ist bislang unbekannt. Man nimmt an, daß eine Wechselwirkung mit dem zweiten membranständigen Protein der Hämagglutinin-Neuraminidase (HN-Protein) die Strukturumwandlung des F-Proteins induziert. Das F-Protein kann jedoch auch in Abwesenheit des HN-Proteins eine Membranfusion vermitteln. Für das Verständnis des Mechanismus der F-proteinvermittelten Fusion ist die Kenntnis der dreidimensionalen Struktur des F-Proteins notwendig. In der vorliegenden Arbeit wurden die F-Proteine der Paramyxoviren, Sendaivirus und Simianvirus 5, in fusionskompetenter Form isoliert und in kleine Lipidvesikel rekonstituiert, um deren Struktur mittels Kryoelektronenmikroskopie und Einzelpartikelanalyse aufzuklären. Die 3D-Struktur des Sendaivirus-F-Proteins konnte mit einer Auflösung von 16 Angström aufgeklärt werden. Es ist die erste 3D-Struktur des F-Proteins eines Paramyxovirus in der fusionskompetenten Form. Um geeignete Bedingungen herauszufinden, die das Auslösen der Konformationsänderung der F-Proteine bzw. das "Einfangen" von Strukturintermediaten während der Fusion ermöglichen, wurde das Fusionsverhalten von Sendaivirus und Simianvirus 5 bei unterschiedlichen Temperatur- und pH-Werten sowie in Anwesenheit von Lysolipiden mittels Fluoreszenzdequenchingassays untersucht. Ein signifikanter Anstieg der Fusionsaktivität der untersuchten Viren konnte durch eine Erhöhung der Temperatur erreicht werden. Mittels ESR-Spektroskopie unter Einsatz von spinmarkierten Lysolipiden konnte gezeigt werden, daß Lysolipide die proteinvermittelte Fusion von Hüllviren in einem späten lipidabhängigen Schritt hemmen. Diese Untersuchungen bilden damit eine Grundlage zur Aufklärung der 3D-Struktur des F-Proteins im fusionsaktiven Zustand. Desweiteren wurde die Rolle der transmembranalen und zytoplasmatischen Domäne des F-Proteins bei der Membranfusion und der Wechselwirkung mit dem HN-Protein mittels Fluoreszenzmikroskopie untersucht. Die Befunde der 3D-Strukturaufklärung und der fluoreszenzmikroskopischen Studien wurden unter anderem in Hinblick auf die Bedeutung der Wechselwirkung zwischen den F- und HN-Proteinen für die Fusion diskutiert. / Paramyxoviruses infect their host cells by fusion of the viral envelope with the cell membrane. The membrane fusion is mediated by a confomational change of a viral envelope glycoprotein called the fusion (F) protein. The trigger of the F protein conformational change is still unknown. It is suggested, that an interaction of the F protein with the second envelope glycoprotein hemagglutinin-neuraminase (HN) induces its conformational change. However the F protein can mediate membrane fusion in absense of HN. The knowledge of the three dimensional structure of the F protein is reqiured to understand the F mediated membrane fusion. In the present work the fusion competent form of the fusion proteins of the paramyxoviruses Sendai virus and Simian virus 5 were isolated and incorporated each of them into small lipid vesicles. The 3D-structure of the entire ectodomain of the Sendai virus F protein has been determined in fusion potential conformation by cryo electron microscopy of single molecules and 3D-reconstruction at a resolution of 16 Angström. To detect usefull conditions for triggering the conformational change of F, the fusion of Sendai virus and Simian virus 5 have been studied at different temperature and pH, respectively, using a fluorescence dequenching assay. A significant increase of virus fusion activity has been found due to temperature enhancement. Using ESR-spectroscopy and spin-labeled lysolipids it has been shown that lysolipids inhibit the protein mediated fusion of enveloped viruses at a late lipid-dependent intermediate. Thus lysolipids are capable to freeze a conformational intermediate of the F protein during fusion. Furthermore the role of the transmembrane and the cytoplasmic domain of the Sendai virus F protein for membrane fusion was investigated using fluorescence microscopy. The results of the fluorescence microscopy study and the detection of the 3D-structure have been discussed in view of the relevance of F-HN-interaction for membrane fusion.

<strong>Background:</strong> Our laboratory identified ELTD1, an orphan GPCR belonging to the adhesion GPCR family (aGPCR), as a novel regulator of angiogenesis and a potential anti-cancer therapeutic target. ELTD1 is normally expressed in both endothelial cells and vascular smooth muscle cells and expression is significantly increased in the tumour vasculature. The aim of this project was to analyse ELTD1's function in endothelial cells and its role in breast cancer. <strong>Method:</strong> 62 sequenced vertebrate genomes were interrogated for ELTD1 conservation and domain alterations. A phylogenetic timetree was assembled to establish time estimates for ELTD1's evolution. After ELTD1 silencing, mRNA array profiling was performed on primary human umbilical vein endothelial cells (HUVECs) and validated with qPCR and confocal microscopy. ELTD1's signalling was investigated by applying the aGPCR ‘Stinger/tethered-agonist Hypothesis'. For this, truncated forms of ELTD1 and peptides analogous to the proposed tethered agonist region were designed. FRET-based 2^nd messenger (Cisbio IP-1;cAMP) and luciferase-reporter assays (NFAT; NFÎoB; SRE; SRF-RE; CREB) were performed to establish canonical GPCR activation. To further investigate ELTD1's role in endothelial cells, ELTD1 was stably overexpressed in HUVECS. Functional angiogenesis assays and mRNA array profiling were then performed. To investigate ELTD1 in breast cancer, a panel of cell lines representative of all molecular subtypes were screened using qPCR. Furthermore, an exploratory pilot study was performed on matched primary and regional nodal secondary breast cancers (n=43) which were stained for ELTD1 expression. Staining intensity was then scored and compared with relapse free survival and overall survival. <strong>Results:</strong> ELTD1 arose 435 million years ago (mya) in bony fish and is present in all subsequent vertebrates. ELTD1 has 3 evolutionary variants of which 2 are most common: one variant with 3 EGFs and a variant with 2 EGFs. Additionally, ELTD1 may be ancestral to members of aGPCR family 2. HUVEC mRNA expression profiling after ELTD1 silencing showed upregulation of the mitochondrial citrate transporter SLC25A1, and ACLY which converts cytoplasmic citrate to Acetyl CoA, feeding fatty acid and cholesterol synthesis, and acetylation. A review of lipid droplet (fatty acid and cholesterol) accumulation by confocal microscopy and flow cytometry (FACS) revealed no changes with ELTD1 silencing. Silencing was also shown to affect the Notch pathway (downregulating the Notch ligand JAG1 and target gene HES2; upregulating the Notch ligand DLL4) and inducing KIT, a mediator of haematopoietic (HSC) and endothelial stem cell (ESC) maintenance. Signalling experiments revealed that unlike other aGPCRs, ELTD1 does not couple to any canonical GPCR pathways (Gαi, Gαs, Gαq, Gα12/13). ELTD1 overexpression in HUVECS revealed that ELTD1 induces an endothelial tip cell phenotype by promoting sprouting and capillary formation, inhibiting lumen anastomoses in mature vessels and lowering proliferation rate. There was no effect on wound healing or adhesion to angiogenesis associated matrix components. Gene expression changes following ELTD1 overexpression included upregulation of angiogenesis associated ANTRX1 as well as JAG1 and downregulation of migration associated CCL15 as well as KIT and DLL4. In breast cancer, none of the representative breast cancer cell lines screened expressed ELTD1. ELTD1 breast cancer immunohistochemistry revealed higher levels of vascular ELTD1 staining intensity within the tumour stroma contrasted to normal stroma and expression within tumour epithelial cells. Additionally, ELTD1 expression in tumour vessels was differentially expressed between the primary breast cancer microenvironment and that of the matched regional node. Due to the small size of the pilot study population, survival comparisons between the various subgroups did not yield significant results. <strong>Conclusion:</strong> ELTD1 is a novel regulator of endothelial metabolism through its suppression of ACLY and the related citrate transporter SLC25A1. ELTD1 also represses KIT, which is known to mediate haematopoietic and endothelial progenitors stem cell maintenance, a possible mechanism through which endothelial cells maintain terminal endothelial differentiation. ELTD1 does not signal like other adhesion GPCRS with CTF and FL forms of ELTD1 not signalling canonically. Additionally, ELTD1 regulates various functions of endothelial cell behaviour and function, inducing an endothelial tip cell phenotype and is highly evolutionarily conserved. Lastly, ELTD1 is differentially expressed in tumour vessels between primary breast cancer and regional nodal metastases and is also expressed in a small subset of breast cancer cells in vivo despite no cancer cell lines expressing ELTD1. The pilot study investigating ELTD1 in the primary breast cancer and regional involved nodes will be followed up with a larger study including the investigation of ELTD1 in distant metastases.

Background: Cystic fibrosis (CF) remains the most common fatal monogenic disease in the US, affecting 1 in 3,300 live births. CF is the result of mutations in CFTR, a chloride channel and regulator of other ion channels. The mechanisms by which CFTR mutations cause chronic lung disease in CF are not fully defined, but may include the combined effects of altered ion and water transport across the airway epithelium and aberrant inflammatory and immune responses to pathogens within the airways. We have shown that Cftr-/- mice mount an exaggerated IgE response towards Aspergillus fumigatus (Af) when compared to Cftr+/+ mice. Along with the increased IgE levels, the Cftr-/- mice had higher levels of IL-13 and IL-4, mimicking both the Th-2 biased immune responses and predilection to mounting Af-specifc IgE seen in CF patients. Herein we hypothesize that these immune aberrations are primarily due to the lack of Cftr expression in lymphocytes rather than with Cftr deficiency in the epithelium. Results: Our results indicate that adoptive transfer experiments with Cf splenocytes confer higher IgE response to Af in host mice as compared to hosts receiving wild-type splenocytes. The predilection of Cftr-deficient lymphocytes to mount Th2 responses was confirmed by in vitro antigen recall experiments, where higher levels of IL-13 and IL-4 where seen only in the presence of Cftr-deficient lymphocytes. Conclusive data on this phenomenon were obtained with conditional Cftr knockout mice, where mice lacking Cftr in T-cell lineages developed the higher IgE titers as compared to their wild-type littermate controls. Further analysis of Cftr-deficient lymphocytes revealed an enhanced intracellular Ca 2+ flux in response to T cell receptor activation as compared to normal lymphocytes. This was accompanied by a significant increase in nuclear localization of the calcium-sensitive transcription factor NFAT, which could contribute to the enhanced secretion of IL-13 and other cytokines. Conclusions: In summary, our data identified that CFTR dysfunction in T cells can lead directly to aberrant immune responses. This is the first instance that a CF related phenotype has been entirely modeled in vivo by selectively knocking out CFTR in the immune system. Specifically, Cftr deficient lymphocytes directed skewed responses to Aspergillus fumigatus , leading to a higher than normal IgE response. These findings implicate the lymphocyte population as a potentially important target for therapeutics directed to the treatment of CF lung disease.

Cystic fibrosis (CF) is caused by mutations in the gene that codes for the chloride channel cystic fibrosis transmembrane conductance regulator (CFTR). Recent advances in CF treatment have included use of small-molecule drugs known as modulators, such as Lumacaftor (VX-809), but their detailed mechanism of action and interplay with the surrounding lipid membranes, including cholesterol, remain largely unknown. To examine these phenomena and guide future modulator development, we prepared a set of wild type (WT) and mutant helical hairpin constructs consisting of CFTR transmembrane (TM) segments 3 and 4 and the intervening extracellular loop (termed TM3/4 hairpins) that represent minimal membrane protein tertiary folding units. These hairpin variants, including CF-phenotypic loop mutants E217G and Q220R, and membrane-buried mutant V232D, were reconstituted into large unilamellar phosphatidylcholine (POPC) vesicles, and into corresponding vesicles containing 70 mol% POPC +30 mol% cholesterol, and studied by single-molecule FRET and circular dichroism experiments. We found that the presence of 30 mol% cholesterol induced an increase in helicity of all TM3/4 hairpins, suggesting an increase in bilayer cross-section and hence an increase in the depth of membrane insertion compared to pure POPC vesicles. Importantly, when we added the corrector VX-809, regardless of the presence or absence of cholesterol, all mutants displayed folding and helicity largely indistinguishable from the WT hairpin. Fluorescence spectroscopy measurements suggest that the corrector alters lipid packing and water accessibility. We propose a model whereby VX-809 shields the protein from the lipid environment in a mutant-independent manner such that the WT scaffold prevails. Such ‘normalization’ to WT conformation is consistent with the action of VX-809 as a protein-folding chaperone.

Les récepteurs couplés aux protéines G (RCPGs) forment la plus grande et la plus diversifiée des familles de protéines localisées à la surface cellulaire et responsables de la transmission de signaux à l’intérieur des cellules. D’intenses recherches effectuées au cours des trente dernières années ont mené à l’identification de dizaines de protéines interagissant avec les RCPGs et contrôlant la signalisation, la désensibilisation, l’internalisation et la dégradation de ces importantes cibles pharmacologiques. Contrairement aux processus régulant l’activité des récepteurs à partir de la membrane plasmique, les mécanismes moléculaires contrôlant la biosynthèse des RCPGs dans le reticulum endoplasmique (RE) et leur transport jusqu’à la surface cellulaire sont très peu caractérisés. Une meilleure compréhension de ces processus nécessite l’identification de la machinerie protéique responsable de la maturation des RCPGs. Un crible protéomique basé sur le transfert d’énergie de résonance de bioluminescence (BRET), qui permet la mesure d’interactions protéiques dans les cellules vivantes, a mené à l’identification de plusieurs nouvelles protéines localisées dans la voie de sécrétion et interagissant potentiellement avec les RCPGs. Ces protéines étant localisées dans les compartiments cellulaires (reticulum endoplasmique et appareil de Golgi) responsables de la synthèse, du repliement adéquat et du transport à la membrane plasmique des récepteurs, il est très probable qu’elles soient impliquées dans le contrôle de l’expression des RCPGs à la surface cellulaire. La caractérisation de l’homologue humain de cornichon 4 (CNIH4), un nouvel intéracteur des RCPGs identifié dans le crible, a démontré que cette protéine localisée dans les compartiments précoces de la voie de sécrétion (RE et ERGIC) interagit de façon sélective avec les RCPGs. De plus, la suppression de l’expression endogène de cette protéine préalablement non-caractérisée, diminue le transport à la membrane plasmique d’un récepteur, indiquant que CNIH4 influence positivement l’export des RCPGs du RE. Ceci est supporté par l’observation que la surexpression de CNIH4 à de faibles niveaux favorise la maturation d’un récepteur mutant normalement retenu dans le RE. Nous avons également pu démontrer que CNIH4 est associée à la protéine Sec23, une des composantes de l’enveloppe des vésicules COPII qui sont responsables du transport des protéines du RE vers le Golgi, suggérant que CNIH4 pourrait favoriser le recrutement des récepteurs dans ces vésicules. La surexpression de CNIH4 à de très hauts niveaux provoque également la rétention intracellulaire des récepteurs. Cet effet dominant négatif pourrait être causé par la titration d’un autre facteur d’export des RCPGs. Une deuxième étude a permis de révéler que la protéine transmembranaire 9 (TMEM9), un nouvel intéracteur des RCPGs également identifié dans le crible, interagit sélectivement avec les récepteurs et avec CNIH4. La surexpression de cette protéine aux fonctions précédemment inconnues, rétablit le transport normal d’un récepteur en présence de CNIH4 surexprimée. De plus, la co-expression de TMEM9 potentialise la capacité de CNIH4 à augmenter la maturation d’un récepteur mutant normalement retenu dans le RE, suggérant que ces deux protéines forment un complexe régulant la maturation des RCPGs. Au cours de cette thèse, de nouvelles protéines interagissant avec les RCPGs et contrôlant leur expression à la membrane plasmique ont donc été identifiées, permettant une meilleure compréhension des mécanismes régulant le transport des récepteurs du RE à la surface cellulaire. / G protein coupled receptors (GPCR) form the largest and most diversified family of cell-surface receptors responsible for signal transduction inside the cells. Extensive research over the last thirty years have led to the identification of multiple proteins interacting with GPCRs and controlling the signalisation, desensitization, internalization and degradation of these important pharmaceutical targets. In contrast to the processes regulating GPCR activity at the plasma membrane, the molecular mechanisms controlling GPCR biogenesis in the endoplasmic reticulum (ER) and their transport to the cell-surface are poorly characterized. The identification of the proteins regulating GPCR maturation is essential in order to understand how receptors are expressed at the plasma membrane. A proteomic screen based on bioluminescence resonance energy transfer (BRET), which allows for the detection of protein-protein interaction in living cells, led to the identification of several potential novel GPCR interactors localized in the secretory pathway. Since the cellular compartments where these proteins are localized are responsible for the synthesis, proper folding and transport to the plasma membrane of the receptors, it is highly probable that they are involve in regulating GPCR cell-surface expression. The characterization of the human cornichon homolog 4 (CNIH4), a novel GPCR interactor identified in the screen, showed that this protein localized in the early secretory pathway (ER and ERGIC), selectively interacts with GPCRs. Knockdown of the endogenous expression of this previously uncharacterized protein led to a decrease in the cell-surface expression of a receptor indicating that CNIH4 has a positive function in the ER export of GPCR. Supporting this, over-expression of CNIH4 at low levels increased the maturation of a mutant receptor normally retained in the ER. Moreover, CNIH4 interacts with Sec23, a component of the inner coat of COPII vesicles which transport proteins from the ER to the Golgi apparatus, suggesting that CNIH4 could recruit GPCRs in these vesicles. CNIH4 over-expression at very high levels also resulted in the intracellular trapping of the receptors. This dominant negative effet could be caused by the titration of another component of the GPCR export process. Another study showed that the transmembrane protein 9 (TMEM9), a novel GPCR interactor also identified in the screen, selectively interacts with GPCRs and CNIH4. Over-expression of this protein of previously unknown function restored normal receptor trafficking in presence of over-expressed CNIH4. Morevover, co-expression of TMEM9 potentialized CNIH4 ability to increase the maturation of a mutant receptor normally retained in the ER, suggesting that these proteins form a complex regulating GPCR maturation. During this thesis, novel GPCR interacting proteins controlling receptor expression at the plasma membrane were identified, allowing for a better understanding of the mechanisms controlling receptor trafficking from the ER to the cell-surface.

Les récepteurs couplés aux protéines G (RCPGs) forment la plus grande et la plus diversifiée des familles de protéines localisées à la surface cellulaire et responsables de la transmission de signaux à l’intérieur des cellules. D’intenses recherches effectuées au cours des trente dernières années ont mené à l’identification de dizaines de protéines interagissant avec les RCPGs et contrôlant la signalisation, la désensibilisation, l’internalisation et la dégradation de ces importantes cibles pharmacologiques. Contrairement aux processus régulant l’activité des récepteurs à partir de la membrane plasmique, les mécanismes moléculaires contrôlant la biosynthèse des RCPGs dans le reticulum endoplasmique (RE) et leur transport jusqu’à la surface cellulaire sont très peu caractérisés. Une meilleure compréhension de ces processus nécessite l’identification de la machinerie protéique responsable de la maturation des RCPGs. Un crible protéomique basé sur le transfert d’énergie de résonance de bioluminescence (BRET), qui permet la mesure d’interactions protéiques dans les cellules vivantes, a mené à l’identification de plusieurs nouvelles protéines localisées dans la voie de sécrétion et interagissant potentiellement avec les RCPGs. Ces protéines étant localisées dans les compartiments cellulaires (reticulum endoplasmique et appareil de Golgi) responsables de la synthèse, du repliement adéquat et du transport à la membrane plasmique des récepteurs, il est très probable qu’elles soient impliquées dans le contrôle de l’expression des RCPGs à la surface cellulaire. La caractérisation de l’homologue humain de cornichon 4 (CNIH4), un nouvel intéracteur des RCPGs identifié dans le crible, a démontré que cette protéine localisée dans les compartiments précoces de la voie de sécrétion (RE et ERGIC) interagit de façon sélective avec les RCPGs. De plus, la suppression de l’expression endogène de cette protéine préalablement non-caractérisée, diminue le transport à la membrane plasmique d’un récepteur, indiquant que CNIH4 influence positivement l’export des RCPGs du RE. Ceci est supporté par l’observation que la surexpression de CNIH4 à de faibles niveaux favorise la maturation d’un récepteur mutant normalement retenu dans le RE. Nous avons également pu démontrer que CNIH4 est associée à la protéine Sec23, une des composantes de l’enveloppe des vésicules COPII qui sont responsables du transport des protéines du RE vers le Golgi, suggérant que CNIH4 pourrait favoriser le recrutement des récepteurs dans ces vésicules. La surexpression de CNIH4 à de très hauts niveaux provoque également la rétention intracellulaire des récepteurs. Cet effet dominant négatif pourrait être causé par la titration d’un autre facteur d’export des RCPGs. Une deuxième étude a permis de révéler que la protéine transmembranaire 9 (TMEM9), un nouvel intéracteur des RCPGs également identifié dans le crible, interagit sélectivement avec les récepteurs et avec CNIH4. La surexpression de cette protéine aux fonctions précédemment inconnues, rétablit le transport normal d’un récepteur en présence de CNIH4 surexprimée. De plus, la co-expression de TMEM9 potentialise la capacité de CNIH4 à augmenter la maturation d’un récepteur mutant normalement retenu dans le RE, suggérant que ces deux protéines forment un complexe régulant la maturation des RCPGs. Au cours de cette thèse, de nouvelles protéines interagissant avec les RCPGs et contrôlant leur expression à la membrane plasmique ont donc été identifiées, permettant une meilleure compréhension des mécanismes régulant le transport des récepteurs du RE à la surface cellulaire. / G protein coupled receptors (GPCR) form the largest and most diversified family of cell-surface receptors responsible for signal transduction inside the cells. Extensive research over the last thirty years have led to the identification of multiple proteins interacting with GPCRs and controlling the signalisation, desensitization, internalization and degradation of these important pharmaceutical targets. In contrast to the processes regulating GPCR activity at the plasma membrane, the molecular mechanisms controlling GPCR biogenesis in the endoplasmic reticulum (ER) and their transport to the cell-surface are poorly characterized. The identification of the proteins regulating GPCR maturation is essential in order to understand how receptors are expressed at the plasma membrane. A proteomic screen based on bioluminescence resonance energy transfer (BRET), which allows for the detection of protein-protein interaction in living cells, led to the identification of several potential novel GPCR interactors localized in the secretory pathway. Since the cellular compartments where these proteins are localized are responsible for the synthesis, proper folding and transport to the plasma membrane of the receptors, it is highly probable that they are involve in regulating GPCR cell-surface expression. The characterization of the human cornichon homolog 4 (CNIH4), a novel GPCR interactor identified in the screen, showed that this protein localized in the early secretory pathway (ER and ERGIC), selectively interacts with GPCRs. Knockdown of the endogenous expression of this previously uncharacterized protein led to a decrease in the cell-surface expression of a receptor indicating that CNIH4 has a positive function in the ER export of GPCR. Supporting this, over-expression of CNIH4 at low levels increased the maturation of a mutant receptor normally retained in the ER. Moreover, CNIH4 interacts with Sec23, a component of the inner coat of COPII vesicles which transport proteins from the ER to the Golgi apparatus, suggesting that CNIH4 could recruit GPCRs in these vesicles. CNIH4 over-expression at very high levels also resulted in the intracellular trapping of the receptors. This dominant negative effet could be caused by the titration of another component of the GPCR export process. Another study showed that the transmembrane protein 9 (TMEM9), a novel GPCR interactor also identified in the screen, selectively interacts with GPCRs and CNIH4. Over-expression of this protein of previously unknown function restored normal receptor trafficking in presence of over-expressed CNIH4. Morevover, co-expression of TMEM9 potentialized CNIH4 ability to increase the maturation of a mutant receptor normally retained in the ER, suggesting that these proteins form a complex regulating GPCR maturation. During this thesis, novel GPCR interacting proteins controlling receptor expression at the plasma membrane were identified, allowing for a better understanding of the mechanisms controlling receptor trafficking from the ER to the cell-surface.